Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Acorda to gain late-stage diazepam spray through Neuronex acquisition

Executive Summary

Acorda Therapeutics Inc. (neuromuscular disorders, multiple sclerosis, and cardiac function) has agreed to acquire Neuronex Inc., a private neurology drug in-licenser, for as much as $10mm initially plus up to a potential $123mm in earn-outs. Neuronex will become a wholly owned subsidiary.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Nasal
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Cash

Related Companies